Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.

Levi O, Dalal N, Komissar A, Moldavsky D, Khamaisi S, Elyagon S, Murninkas M, Eliyahu A, Burg S, Attali B, Makarovsky D, Lichtenstein A and 6 more

Show all authors

Gradwohl G, Tsaban G, Kakzanov Y, Laish-Farkash A, Etzion S, Etzion Y

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology1 May 2026Cited by 2 (Europe PMC)

PMID42015513PMCIDPMC13191121DOI10.1093/europace/euag091PepBankPUB-42015513

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In post-infarction rats with reduced ejection fraction, semaglutide reduced atrial fibrillation inducibility.
In plain wordsIn rats with heart damage after a heart attack, semaglutide made atrial fibrillation harder to trigger.
Peptide
Semaglutide
Outcome
DecreaseAtrial fibrillation inducibility
Study
ratn: not reported in source
Post-myocardial infarction rats with reduced ejection fraction
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
40 µg/kg every 72 h · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
Both semaglutide and colchicine reduced AF inducibility
1 context sentence(design, population, supporting numbers)
Summary · context
One-week post-MI, animals with left ventricular ejection fraction ≤40% were randomized to semaglutide (40 µg/kg subcutaneously every 72 h), colchicine (100 µg/kg intraperitoneally daily), or vehicle for 21 days.
Report a problemFND-4201551301
02AnimalAnimal study (in vivo)Efficacy outcome
In post-infarction rats with reduced ejection fraction, semaglutide reduced atrial fibrillation duration.
In plain wordsIn rats with heart damage after a heart attack, semaglutide shortened episodes of atrial fibrillation.
Peptide
Semaglutide
Outcome
DecreaseAtrial fibrillation duration
Study
ratn: not reported in source
Post-myocardial infarction rats with reduced ejection fraction
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
40 µg/kg every 72 h · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
Both semaglutide and colchicine reduced AF inducibility and AF duration, whereas semaglutide additionally reduced atrial signal complexity.
1 context sentence(design, population, supporting numbers)
Summary · context
One-week post-MI, animals with left ventricular ejection fraction ≤40% were randomized to semaglutide (40 µg/kg subcutaneously every 72 h), colchicine (100 µg/kg intraperitoneally daily), or vehicle for 21 days.
Report a problemFND-4201551302
03AnimalAnimal study (in vivo)Efficacy outcome
In post-infarction rats with reduced ejection fraction, semaglutide reduced atrial signal complexity, which colchicine was not reported to do.
In plain wordsIn rats with heart damage after a heart attack, semaglutide reduced the complexity of atrial electrical signals.
Peptide
Semaglutide
Outcome
DecreaseAtrial signal complexity
Study
ratn: not reported in source
Post-myocardial infarction rats with reduced ejection fraction
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
40 µg/kg every 72 h · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
whereas semaglutide additionally reduced atrial signal complexity.
1 context sentence(design, population, supporting numbers)
Summary · context
One-week post-MI, animals with left ventricular ejection fraction ≤40% were randomized to semaglutide (40 µg/kg subcutaneously every 72 h), colchicine (100 µg/kg intraperitoneally daily), or vehicle for 21 days.
Report a problemFND-4201551303
04AnimalAnimal study (in vivo)Efficacy outcome
In post-infarction rats with reduced ejection fraction, semaglutide attenuated atrial fibrosis.
In plain wordsIn rats with heart damage after a heart attack, semaglutide reduced scarring in the upper heart chambers.
Peptide
Semaglutide
Outcome
DecreaseAtrial fibrosis
Study
ratn: not reported in source
Post-myocardial infarction rats with reduced ejection fraction
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
40 µg/kg every 72 h · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
Semaglutide attenuated atrial fibrosis
1 context sentence(design, population, supporting numbers)
Summary · context
One-week post-MI, animals with left ventricular ejection fraction ≤40% were randomized to semaglutide (40 µg/kg subcutaneously every 72 h), colchicine (100 µg/kg intraperitoneally daily), or vehicle for 21 days.
Report a problemFND-4201551304
05AnimalAnimal study (in vivo)Mechanism
In post-infarction rats with reduced ejection fraction, semaglutide suppressed atrial NLRP3 inflammasome expression.
In plain wordsIn rats with heart damage after a heart attack, semaglutide lowered an inflammation-related protein in the atria.
Peptide
Semaglutide
Outcome
DecreaseNLRP3 inflammasome expression
Study
ratn: not reported in source
Post-myocardial infarction rats with reduced ejection fraction
Comparator
Vehicle
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
40 µg/kg every 72 h · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
suppressed NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome expression
1 context sentence(design, population, supporting numbers)
Summary · context
One-week post-MI, animals with left ventricular ejection fraction ≤40% were randomized to semaglutide (40 µg/kg subcutaneously every 72 h), colchicine (100 µg/kg intraperitoneally daily), or vehicle for 21 days.
Report a problemFND-4201551305
06AnimalAnimal study (in vivo)Mechanism
In post-infarction rats with reduced ejection fraction, semaglutide prevented connexin-43 lateralization.
In plain wordsIn rats with heart damage after a heart attack, semaglutide prevented a harmful shift in the position of a heart cell channel protein.
Peptide
Semaglutide
Outcome
DecreaseConnexin-43 lateralization
Study
ratn: not reported in source
Post-myocardial infarction rats with reduced ejection fraction
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
40 µg/kg every 72 h · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
prevented connexin-43 (Cx43) lateralization
1 context sentence(design, population, supporting numbers)
Summary · context
One-week post-MI, animals with left ventricular ejection fraction ≤40% were randomized to semaglutide (40 µg/kg subcutaneously every 72 h), colchicine (100 µg/kg intraperitoneally daily), or vehicle for 21 days.
Report a problemFND-4201551306
07AnimalAnimal study (in vivo)Mechanism
In post-infarction rats with reduced ejection fraction, semaglutide reduced expression of the proarrhythmic SK4 potassium channel.
In plain wordsIn rats with heart damage after a heart attack, semaglutide lowered a potassium channel protein linked to irregular heartbeat.
Peptide
Semaglutide
Outcome
DecreaseSK4 channel expression
Study
ratn: not reported in source
Post-myocardial infarction rats with reduced ejection fraction
Comparator
Vehicle
Outcome group
Heart function · Cardiovascular
Studied dose
40 µg/kg every 72 h · subcutaneous · 21 daysAs given in this study (rat).
Source sentences
Summary
reduced expression of the proarrhythmic small-conductance calcium-activated potassium channel 4 (SK4)
1 context sentence(design, population, supporting numbers)
Summary · context
One-week post-MI, animals with left ventricular ejection fraction ≤40% were randomized to semaglutide (40 µg/kg subcutaneously every 72 h), colchicine (100 µg/kg intraperitoneally daily), or vehicle for 21 days.
Report a problemFND-4201551307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords